{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:41:09Z","timestamp":1793108469009,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10549-026-08088-z","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:11:13Z","timestamp":1790604673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer"],"prefix":"10.1007","volume":"219","author":[{"given":"Payu","family":"Raval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaaeddin","family":"Alrohaibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerollos Nashat","family":"Wanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-9624","authenticated-orcid":false,"given":"Aysegul","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"8088_CR1","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2021.05.005","volume":"32","author":"F Schettini","year":"2021","unstructured":"Schettini F, Pascual T, Conte B et al (2021) HER2-low breast cancer: biological and clinical implications. Ann Oncol 32:1056\u20131068. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.005","journal-title":"Ann Oncol"},{"key":"8088_CR2","doi-asserted-by":"publisher","first-page":"8093","DOI":"10.1245\/s10434-024-15332-0","volume":"31","author":"J Tchou","year":"2024","unstructured":"Tchou J, Gottipati S, Goldbach M et al (2024) Change in biomarker profile after neoadjuvant chemotherapy is prognostic and common among patients with HER2\u2009+\u2009breast cancer. Ann Surg Oncol 31:8093\u20138101. https:\/\/doi.org\/10.1245\/s10434-024-15332-0","journal-title":"Ann Surg Oncol"},{"key":"8088_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1056\/NEJMoa2406070","volume":"392","author":"CE Geyer","year":"2025","unstructured":"Geyer CE, Untch M, Huang CS et al (2025) Survival with trastuzumab emtansine in residual HER2-positive breast cancer. N Engl J Med 392:249\u2013257. https:\/\/doi.org\/10.1056\/NEJMoa2406070","journal-title":"N Engl J Med"},{"key":"8088_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMoa2514661","volume":"394","author":"S Loibl","year":"2026","unstructured":"Loibl S, Park YH, Shao Z et al (2026) Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med 394:845\u2013857. https:\/\/doi.org\/10.1056\/NEJMoa2514661","journal-title":"N Engl J Med"},{"key":"8088_CR5","first-page":"2564","volume":"13","author":"D Uczkowski","year":"2023","unstructured":"Uczkowski D, Sekhri A, Gupta S et al (2023) Treatment of HER2\u2009+\u2009breast cancer: prognosis with loss of HER2 amplification after neoadjuvant therapy. Am J Cancer Res 13:2564\u20132571","journal-title":"Am J Cancer Res"},{"key":"8088_CR6","doi-asserted-by":"publisher","first-page":"113920","DOI":"10.1016\/j.ejca.2024.113920","volume":"201","author":"P Tarantino","year":"2024","unstructured":"Tarantino P, Ajari O, Graham N et al (2024) Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer. Eur J Cancer 201:113920. https:\/\/doi.org\/10.1016\/j.ejca.2024.113920","journal-title":"Eur J Cancer"},{"key":"8088_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.clbc.2025.10.017","volume":"26","author":"M Antonini","year":"2026","unstructured":"Antonini M, Mattar A, Facina G et al (2026) Immunohistochemical changes after neoadjuvant chemotherapy and their impact on breast cancer survival: a systematic review and meta-analysis. Clin Breast Cancer 26:208\u2013222e11. https:\/\/doi.org\/10.1016\/j.clbc.2025.10.017","journal-title":"Clin Breast Cancer"},{"key":"8088_CR8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/annonc\/mdv611","volume":"27","author":"N Niikura","year":"2016","unstructured":"Niikura N, Tomotaki A, Miyata H et al (2016) Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol 27:480\u2013487. https:\/\/doi.org\/10.1093\/annonc\/mdv611","journal-title":"Ann Oncol"},{"key":"8088_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1309\/AJCP1YVYJXKZQJHX","volume":"142","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Seo AN, Kim EJ et al (2014) HER2 heterogeneity affects trastuzumab response. Am J Clin Pathol 142:755\u2013766. https:\/\/doi.org\/10.1309\/AJCP1YVYJXKZQJHX","journal-title":"Am J Clin Pathol"},{"key":"8088_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13059-015-0652-6","volume":"16","author":"CKY Ng","year":"2015","unstructured":"Ng CKY, Martelotto LG, Gauthier A et al (2015) Intratumor genetic heterogeneity in HER2-amplified breast cancer. Genome Biol 16:107. https:\/\/doi.org\/10.1186\/s13059-015-0652-6","journal-title":"Genome Biol"},{"key":"8088_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab deruxtecan in previously treated HER2-low breast cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"8088_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41523-022-00412-2","volume":"8","author":"F Miglietta","year":"2022","unstructured":"Miglietta F, Griguolo G, Bottosso M et al (2022) HER2-low evolution after neoadjuvant therapy. NPJ Breast Cancer 8:66. https:\/\/doi.org\/10.1038\/s41523-022-00412-2","journal-title":"NPJ Breast Cancer"},{"key":"8088_CR13","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105\u20132122. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"8088_CR14","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R et al (2024) Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 391:2110\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa2407086","journal-title":"N Engl J Med"},{"key":"8088_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","volume":"138","author":"AC Wolff","year":"2014","unstructured":"Wolff AC, Hammond ME, Hicks DG et al (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138:241\u2013256. https:\/\/doi.org\/10.5858\/arpa.2013-0953-SA","journal-title":"Arch Pathol Lab Med"},{"key":"8088_CR16","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2006.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414\u20134422. https:\/\/doi.org\/10.1200\/JCO.2006.10.6823","journal-title":"J Clin Oncol"},{"key":"8088_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41379-021-00738-5","volume":"34","author":"A Katayama","year":"2021","unstructured":"Katayama A, Miligy IM, Shiino S et al (2021) Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Mod Pathol 34:1271\u20131281. https:\/\/doi.org\/10.1038\/s41379-021-00738-5","journal-title":"Mod Pathol"},{"key":"8088_CR18","doi-asserted-by":"publisher","first-page":"10647","DOI":"10.1002\/cam4.5817","volume":"12","author":"A LeVee","year":"2023","unstructured":"LeVee A, Spector K, Larkin B et al (2023) Incidence and prognostic impact of HER2-positivity loss after dual HER2-directed neoadjuvant therapy for HER2\u2009+\u2009breast cancer. Cancer Med 12:10647\u201310659. https:\/\/doi.org\/10.1002\/cam4.5817","journal-title":"Cancer Med"},{"key":"8088_CR19","doi-asserted-by":"publisher","first-page":"e34903","DOI":"10.1097\/MD.0000000000034903","volume":"102","author":"X Ren","year":"2023","unstructured":"Ren X, Zhang X, Ma X et al (2023) Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment. Med (Baltim) 102:e34903. https:\/\/doi.org\/10.1097\/MD.0000000000034903","journal-title":"Med (Baltim)"},{"key":"8088_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10549-019-05173-4","volume":"175","author":"T Ignatov","year":"2019","unstructured":"Ignatov T, Gorbunow F, Eggemann H et al (2019) Loss of HER2 after HER2-targeted treatment. Breast Cancer Res Treat 175:401\u2013408. https:\/\/doi.org\/10.1007\/s10549-019-05173-4","journal-title":"Breast Cancer Res Treat"},{"key":"8088_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.humpath.2023.11.003","volume":"142","author":"C Karakas","year":"2023","unstructured":"Karakas C, Tyburski H, Turner BM et al (2023) HER2 categorical changes after neoadjuvant chemotherapy: a study of 192 matched breast cancers with the inclusion of HER2-low category. Hum Pathol 142:34\u201341. https:\/\/doi.org\/10.1016\/j.humpath.2023.11.003","journal-title":"Hum Pathol"},{"key":"8088_CR22","doi-asserted-by":"publisher","first-page":"1522460","DOI":"10.3389\/fonc.2025.1522460","volume":"15","author":"J Wang","year":"2025","unstructured":"Wang J, Long X, Tang M, Xiao X (2025) HER2 and hormone receptor conversion after neoadjuvant therapy for breast cancer. Front Oncol 15:1522460. https:\/\/doi.org\/10.3389\/fonc.2025.1522460","journal-title":"Front Oncol"},{"key":"8088_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2015.73","volume":"12","author":"D Zardavas","year":"2015","unstructured":"Zardavas D, Irrthum A, Swanton C et al (2015) Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol 12:381\u2013394. https:\/\/doi.org\/10.1038\/nrclinonc.2015.73","journal-title":"Nat Rev Clin Oncol"},{"key":"8088_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-016-4084-8","volume":"162","author":"D Ma","year":"2017","unstructured":"Ma D, Jiang YZ, Liu XY et al (2017) Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer. Breast Cancer Res Treat 162:39\u201348. https:\/\/doi.org\/10.1007\/s10549-016-4084-8","journal-title":"Breast Cancer Res Treat"},{"key":"8088_CR25","doi-asserted-by":"publisher","first-page":"100785","DOI":"10.1016\/j.modpat.2025.100785","volume":"38","author":"W Dai","year":"2025","unstructured":"Dai W, Navolotskaia O, Fine JL et al (2025) Not all HER2-positive breast cancers are the same: intratumoral heterogeneity, low-level HER2 amplification, and their impact on neoadjuvant therapy response. Mod Pathol 38:100785. https:\/\/doi.org\/10.1016\/j.modpat.2025.100785","journal-title":"Mod Pathol"},{"key":"8088_CR26","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","volume":"11","author":"OM Filho","year":"2021","unstructured":"Filho OM, Viale G, Stein S et al (2021) Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov 11:2474\u20132487. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1557","journal-title":"Cancer Discov"},{"key":"8088_CR27","doi-asserted-by":"publisher","first-page":"e176454","DOI":"10.1172\/JCI176454","volume":"134","author":"Z Li","year":"2024","unstructured":"Li Z, Metzger Filho O, Viale G et al (2024) HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. J Clin Invest 134:e176454. https:\/\/doi.org\/10.1172\/JCI176454","journal-title":"J Clin Invest"},{"key":"8088_CR28","doi-asserted-by":"publisher","first-page":"100935","DOI":"10.1016\/j.modpat.2025.100935","volume":"39","author":"J Hu","year":"2026","unstructured":"Hu J, Tsang JY, Liu J et al (2026) Predictors of response to neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2)-positive breast cancer and pathological evaluation of HER2 heterogeneity. Mod Pathol 39:100935. https:\/\/doi.org\/10.1016\/j.modpat.2025.100935","journal-title":"Mod Pathol"},{"key":"8088_CR29","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3390\/cancers17132126","volume":"17","author":"T Hatano","year":"2025","unstructured":"Hatano T, Tanei T, Seno S et al (2025) High HER2 intratumoral heterogeneity is resistant to anti-HER2 neoadjuvant chemotherapy in early stage and locally advanced HER2-positive breast cancer. Cancers (Basel) 17:2126. https:\/\/doi.org\/10.3390\/cancers17132126","journal-title":"Cancers (Basel)"},{"key":"8088_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41467-019-08593-4","volume":"10","author":"JL Caswell-Jin","year":"2019","unstructured":"Caswell-Jin JL, McNamara K, Reiter JG et al (2019) Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nat Commun 10:657. https:\/\/doi.org\/10.1038\/s41467-019-08593-4","journal-title":"Nat Commun"},{"key":"8088_CR31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-1459","author":"MA Goyette","year":"2026","unstructured":"Goyette MA, Graser C, Seehawer M et al (2026) HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-25-1459","journal-title":"Cancer Discov"},{"key":"8088_CR32","doi-asserted-by":"publisher","first-page":"102923","DOI":"10.1016\/j.ctrv.2025.102923","volume":"135","author":"S Nakatani","year":"2025","unstructured":"Nakatani S, Hayashi T, Yamamoto K, Maeda H (2025) Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: a systematic review and meta-analysis. Cancer Treat Rev 135:102923. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102923","journal-title":"Cancer Treat Rev"},{"key":"8088_CR33","doi-asserted-by":"publisher","first-page":"104516","DOI":"10.1016\/j.breast.2025.104516","volume":"82","author":"GP Dowling","year":"2025","unstructured":"Dowling GP, Daly GR, Hehir CM et al (2025) Prognostic significance of receptor conversion following neoadjuvant therapy in breast cancer: a systematic review and meta-analysis. Breast 82:104516. https:\/\/doi.org\/10.1016\/j.breast.2025.104516","journal-title":"Breast"},{"key":"8088_CR34","doi-asserted-by":"publisher","first-page":"103586","DOI":"10.1016\/j.breast.2023.103586","volume":"72","author":"JP Mogica","year":"2023","unstructured":"Mogica JP, Tang H, Liang Y et al (2023) Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: a single institution experience and review of the literature. Breast 72:103586. https:\/\/doi.org\/10.1016\/j.breast.2023.103586","journal-title":"Breast"},{"key":"8088_CR35","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/jso.26646","volume":"124","author":"CL Wetzel","year":"2021","unstructured":"Wetzel CL, Sutton TL, Gardiner S et al (2021) Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes. J Surg Oncol 124:1224\u20131234. https:\/\/doi.org\/10.1002\/jso.26646","journal-title":"J Surg Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08088-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08088-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08088-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:57:37Z","timestamp":1793105857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08088-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8088"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08088-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. The study was approved by The University of Texas MD Anderson Cancer Center Institutional Review Board.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable (This is a retrospective study).","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MCM has served as a consultant for Exact Sciences, Novartis, Astra Zeneca, Pfizer and Genentech.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25"}}